---
title: "Cytokinetics CEO Robert I. Blum sells 7,500 common shares for $575,700"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295452544.md"
description: "Cytokinetics CEO Robert I. Blum exercised 7,500 stock options at $10.60 and sold the resulting shares for $575,700 on August 10, 2026. Following these transactions, his direct holdings of common shares decreased to 377,820."
datetime: "2026-08-10T21:13:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295452544.md)
  - [en](https://longbridge.com/en/news/295452544.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295452544.md)
generator: "portal-rs"
---

# Cytokinetics CEO Robert I. Blum sells 7,500 common shares for $575,700

-   Cytokinetics President and CEO Robert I. Blum exercised 7,500 stock options at USD 10.6 on Aug. 10, 2026. \* Blum sold 7,500 shares at USD 76.76 the same day. \* Directly held common shares fell to 377,820 following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000087), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)

## Related News & Research

- [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370](https://longbridge.com/en/news/296267986.md)
- [Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale](https://longbridge.com/en/news/296290252.md)
- [Cytokinetics grants new-hire equity awards, stock options priced at $74.13 per share](https://longbridge.com/en/news/296264145.md)
- [Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative](https://longbridge.com/en/news/296006872.md)
- [Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525](https://longbridge.com/en/news/293972048.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**